Clinical Trials Browser

Phase 1/2 × OTHER_GOV × Fulvestrant × Clear all

NCT01992952 2025-11-26

FAKTION

Phase 1/2 Active not recruiting

Estrogen Receptor Positive Breast Cancer

NCT05176080 2024-12-17

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms